169 related articles for article (PubMed ID: 31556823)
21. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
22. Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.
Jiang Q; Wang H; Yu L; Gale RP
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2619-2630. PubMed ID: 28894944
[TBL] [Abstract][Full Text] [Related]
23. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
Henk HJ; Woloj M; Shapiro M; Whiteley J
Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
[TBL] [Abstract][Full Text] [Related]
24. Assessing the association between medication adherence, as defined in quality measures, and disease-state control, health care utilization, and costs in a retrospective database analysis of Medicare supplemental beneficiaries using statin medications.
Axon DR; Vaffis S; Chinthammit C; Lott BE; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
J Manag Care Spec Pharm; 2020 Dec; 26(12):1529-1537. PubMed ID: 33251989
[No Abstract] [Full Text] [Related]
25. Integrating E-Prescribing and Pharmacy Claims Data for Predictive Modeling: Comparing Costs and Utilization of Health Plan Members Who Fill Their Initial Medications with Those Who Do Not.
Chang HY; Kan HJ; Shermock KM; Alexander GC; Weiner JP; Kharrazi H
J Manag Care Spec Pharm; 2020 Oct; 26(10):1282-1290. PubMed ID: 32996394
[TBL] [Abstract][Full Text] [Related]
26. Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States.
Seiter K; Latremouille-Viau D; Guerin A; Ndife B; Habucky K; Tang DH; Pivneva I; Gagnon-Sanschagrin P; Joseph GJ
Adv Ther; 2018 Oct; 35(10):1671-1685. PubMed ID: 30155792
[TBL] [Abstract][Full Text] [Related]
27. Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Dashputre AA; Gatwood KS; Gatwood J
J Manag Care Spec Pharm; 2020 Feb; 26(2):186-196. PubMed ID: 32011965
[TBL] [Abstract][Full Text] [Related]
28. Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status.
Kenzik KM; Bhatia R; Bhatia S
JAMA Oncol; 2020 Apr; 6(4):542-546. PubMed ID: 31999305
[TBL] [Abstract][Full Text] [Related]
29. Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US.
Jabbour EJ; Mendiola MF; Lingohr-Smith M; Lin J; Makenbaeva D
J Med Econ; 2019 Nov; 22(11):1113-1118. PubMed ID: 31074658
[No Abstract] [Full Text] [Related]
30. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
Nguyen JT; Cole AL; Leech AA; Wood WA; Dusetzina SB
Value Health; 2020 Oct; 23(10):1292-1299. PubMed ID: 33032772
[TBL] [Abstract][Full Text] [Related]
31. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
[TBL] [Abstract][Full Text] [Related]
32. The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Guérin A; Wu EQ; Bollu VK; Williams D; Guo A; de Leon DP; Quintas-Cardama A
J Med Econ; 2013; 16(1):125-33. PubMed ID: 22587385
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans.
Kreys ED; Frei CR; Villarreal SM; Bollinger MJ; Jones X; Koeller JM
Pharmacotherapy; 2017 Mar; 37(3):278-286. PubMed ID: 28052354
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
35. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
Jiang Q; Wang HB; Yu L; Gale RP
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
[TBL] [Abstract][Full Text] [Related]
36. Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
Winn AN; Atallah E; Cortes J; Deininger MWN; Kota V; Larson RA; Moore JO; Mauro MJ; Oehler VG; Pinilla-Ibarz J; Radich JP; Shah NP; Thompson JE; Flynn KE
JAMA Netw Open; 2023 Dec; 6(12):e2347950. PubMed ID: 38109114
[TBL] [Abstract][Full Text] [Related]
37. [Analysis on tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the real world: experience from single center].
Yu L; Qin YZ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):754-760. PubMed ID: 29081191
[No Abstract] [Full Text] [Related]
38. [Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020].
Wang HF; Zhang YL; Liu XL; Zhu HL; Liang R; Liu BC; Zhou L; Meng L; Li WM; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):535-542. PubMed ID: 34455739
[No Abstract] [Full Text] [Related]
39. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.
Ta JT; Sullivan SD; Tung A; Oliveri D; Gillard P; Devine B
J Manag Care Spec Pharm; 2021 Feb; 27(2):223-239. PubMed ID: 33506730
[No Abstract] [Full Text] [Related]
40. Treatment Initiation Patterns, Modifications, and Medication Adherence Among Newly Diagnosed Heart Failure Patients: A Retrospective Claims Database Analysis.
Deschaseaux C; McSharry M; Hudson E; Agrawal R; Turner SJ
J Manag Care Spec Pharm; 2016 May; 22(5):561-71. PubMed ID: 27123917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
